This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter,
outpatient study in subjects with schizophrenia with an inadequate response to their
current atypical antipsychotic treatment. The primary objective of the study is to assess
the efficacy of adjunctive KarXT (a fixed dose combination of xanomeline and trospium
chloride twic...Read More
e daily [BID]) versus placebo in the treatment of subjects with inadequately
controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome
Scale (PANSS) Total Score.Read Less
Ask a Question?
Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others
Please enter valid email address.
Please enter all required fields.
